In a report published Wednesday, D.A. Davidson analyst Tim Ramey reiterated a Neutral rating on USANA Health Sciences USNA, and raised the price target from $80.00 to $92.00.
In the report, D.A. Davidson noted, “Q2 operating EPS of $1.72 was up ~55% from $1.11 last year, exceeding our $1.23 estimate and the 5-analyst Street mean of $1.33. Results were driven by sales increases in the Asia Pacific and North America/Europe segments, as well as a $1.2 million benefit from favorable exchange rates. The tax rate of 33.4% was 40bp higher than our forecast. Net sales of $189.1 million increased 17.5% year-over-year. On a segment basis, sales in North America grew 6.9%, SE Asia/Pacific was up 9.3%, China increased 36.3%, and North Asia climbed 1.5%. Total Active Associates' growth was 8.1%, led by Greater China, which grew 18.4%. North Asia was the second fastest growing segment, up 12.5%. Active Associates in SE Asia/Pacific grew 3.4%, while North America was flat.”
USANA Health Sciences closed on Tuesday at $80.55.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.